Psychedelic perceptions: mental health service user attitudes to psilocybin therapy

Corrigan, Kate; Haran, Maeve; McCandliss, Conor; McManus, Róisín M.; Cleary, Shannon; Trant, Rebecca; Kelly, Yazeed; Ledden, Kathryn; Rush, Gavin; O’Keane, Veronica; Kelly, John R.

doi:10.1007/s11845-021-02668-2

Cited by 29 publications

(22 citation statements)

References 82 publications

(77 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Translational Psychedelic science is evolving rapidly (1)(2)(3). Initial data suggests that the dose dependent, transient, altered state of information processing induced by psychedelics can be harnessed by the psychotherapeutic process to lead to clinical benefits across a range of disorders.…”

Section: Introductionmentioning

confidence: 99%

Psychedelic Therapy's Transdiagnostic Effects: A Research Domain Criteria (RDoC) Perspective

et al. 2021

Self Cite

View full text Add to dashboard Cite

Accumulating clinical evidence shows that psychedelic therapy, by synergistically combining psychopharmacology and psychological support, offers a promising transdiagnostic treatment strategy for a range of disorders with restricted and/or maladaptive habitual patterns of emotion, cognition and behavior, notably, depression (MDD), treatment resistant depression (TRD) and addiction disorders, but perhaps also anxiety disorders, obsessive-compulsive disorder (OCD), Post-Traumatic Stress Disorder (PTSD) and eating disorders. Despite the emergent transdiagnostic evidence, the specific clinical dimensions that psychedelics are efficacious for, and associated underlying neurobiological pathways, remain to be well-characterized. To this end, this review focuses on pre-clinical and clinical evidence of the acute and sustained therapeutic potential of psychedelic therapy in the context of a transdiagnostic dimensional systems framework. Focusing on the Research Domain Criteria (RDoC) as a template, we will describe the multimodal mechanisms underlying the transdiagnostic therapeutic effects of psychedelic therapy, traversing molecular, cellular and network levels. These levels will be mapped to the RDoC constructs of negative and positive valence systems, arousal regulation, social processing, cognitive and sensorimotor systems. In summarizing this literature and framing it transdiagnostically, we hope we can assist the field in moving toward a mechanistic understanding of how psychedelics work for patients and eventually toward a precise-personalized psychedelic therapy paradigm.

show abstract

Section: Introductionmentioning

confidence: 99%

Psychedelic Therapy's Transdiagnostic Effects: A Research Domain Criteria (RDoC) Perspective

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…We propose that psychedelic research built on open and trusting PPI will result in superior outcomes and experiences for participants. The vocabulary used when developing participant information, outcome measures and interventions for psychedelic research might feel alienating or less socially acceptable to some audiences (72). Seeking the advice of others can help build empathy and help researchers to understand the fears and beliefs of potential participants of psychedelic research.…”

Section: Discussionmentioning

confidence: 99%

Co-design of Guidance for Patient and Public Involvement in Psychedelic Research

Bornemann

Piggin

et al. 2021

Front. Psychiatry

View full text Add to dashboard Cite

Within the context of scientific research, patient and public involvement (PPI) is defined as research performed “with” or “by” patients and members of the public, rather than “to,” “about”, or “for” them. When carried out systematically and thoughtfully, PPI has the potential to strengthen the quality and impact of research by fostering accountability, transparency, and relevance. There exist numerous guidelines, frameworks and tools for supporting PPI, however, these do not account for the unique challenges faced in psychedelic research. This paper describes the co-design of guidance intended to help build, evaluate and improve PPI in psychedelic research. A steering group was formed to design and run a co-design workshop alongside public collaborators. Insights from this workshop were analyzed and refined into a comprehensive and readily usable guide for planning PPI specific to the field of psychedelic research. Core values emerging from the process focused on the essential importance of trust, learning, purpose and inclusivity. It is hoped that this guidance will be a starting point for incorporating PPI in future psychedelic research, so that it can grow and adapt as this burgeoning field of research progresses.

show abstract

“…The uncertainty surrounding PAP was an important theme and showed that Psychiatrists are not just uncertain about their own role in PAP, but also the uncertain risks and benefits for patients. Recent research from Ireland suggested that just over a half of mental health service users would accept treatment with PAP if a doctor recommended it (18). It seems likely that psychiatrists will be increasingly asked about PAP by patients and be expected to have a working knowledge or who it benefits and how to access it.…”

Section: Discussionmentioning

confidence: 99%

The Readiness of Psychiatrists to Implement Psychedelic-Assisted Psychotherapy

et al. 2021

View full text Add to dashboard Cite

Introduction: Psychedelic-assisted psychotherapy is a promising approach in psychiatry; evidence is growing and it may not be long before mainstream services are expected to offer it to selected patients. This pilot study examined the attitudes and knowledge of NHS psychiatrists of all levels towards psychedelic-assisted psychotherapy and explored potential barriers and facilitators to its implementation.Methods: A mixed-methods approach was adopted, using a cross-sectional survey and focus groups. All psychiatrists in one NHS mental health trust were approached by email to participate. The survey was analysed using a simple descriptive approach and thematic analysis was used for the focus groups.Results: Eighty-three (25.7%) psychiatrists participated in the survey. All psychiatrists were familiar with one or more psychedelic substances. Although 77.2% felt that there should be a role for controlled or therapeutic use of psychedelics, trainees appeared better informed than non-training grade psychiatrists. Psychiatrists of all grades did not feel prepared to participate in the delivery of psychedelic-assisted psychotherapy. Thematic analysis of the focus groups identified three main themes in relation to psychedelic-assisted psychotherapy: “need for knowledge,” “openness to change,” and “uncertainty.”Discussion: NHS psychiatrists are positive about the potential for psychedelic-assisted therapy to advance psychiatric practise. However, psychiatrists are lacking in confidence or preparedness to implement this treatment should it become a mainstream option and significant training needs were identified. Thematic analysis highlighted the need for societal shifts as well as professional ones.

show abstract

Psychedelic perceptions: mental health service user attitudes to psilocybin therapy

Cited by 29 publications

References 82 publications

Psychedelic Therapy's Transdiagnostic Effects: A Research Domain Criteria (RDoC) Perspective

Psychedelic Therapy's Transdiagnostic Effects: A Research Domain Criteria (RDoC) Perspective

Co-design of Guidance for Patient and Public Involvement in Psychedelic Research

The Readiness of Psychiatrists to Implement Psychedelic-Assisted Psychotherapy

Contact Info

Product

Resources

About